Journal Logo

May 2021 - Volume 5 - Issue 5
pp: e560-e560







Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

Mesa, Ruben A.; Schaap, Nicolaas; Vannucchi, Alessandro M.; More

HemaSphere. 5(5):e553, May 2021.

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; More

HemaSphere. 5(5):e562, May 2021.

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

Holthof, Lisa C.; Stikvoort, Arwen; van der Horst, Hilma J.; More

HemaSphere. 5(5):e561, May 2021.